Answers are grounded in this paper and cite their sources.
Prolyl-endopeptidase supplementation has been proposed to favour gliadin degradation as an alternative treatment for coeliac disease (CD), although the real usefulness of this therapy in vivo is still under discussion. 1 However, our data point to alternative treatments aiming to modify the intestinal microbiota in patients with CD by the use of probiotics and/or prebiotics. We propose that the induction of gliadin proteolysis in the human gut might not be the solution but the origin of CD.
No takes yet. Share an insight, caveat, or question.
Bernardo et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: